{
    "clinical_study": {
        "@rank": "16", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give 1592U89 to\n      HIV-positive adults. This study also examines the influence previous anti-HIV treatment has\n      on the effectiveness of 1592U89."
        }, 
        "brief_title": "A Study of 1592U89 in HIV-Infected Adults", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive open-label 1592U89 administered orally in combination with at least one\n      other antiretroviral agent that the patient has not previously received."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        Erythropoietin, G-CSF and GM-CSF.\n\n        Patients must have:\n\n          -  CD4+ cell count < 100 cells/mm3.\n\n          -  HIV-1 RNA > 30,000 copies/ml.\n\n          -  Signed, informed consent from parent or legal guardian for patient under 18 years of\n             age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Renal failure requiring dialysis.\n\n          -  Hepatic failure evident by grade 3/4 hyperbilirubinemia and AST 5 times the upper\n             limit of normal.\n\n          -  Documented hypersensitivity to 1592U89.\n\n          -  Serious medical conditions, such as diabetes, congestive heart failure,\n             cardiomyopathy, or other cardiac dysfunction, that would compromise the safety of the\n             patient.\n\n          -  Participation in or ability to participate in an enrolling study of 1592U89.\n\n        Required:\n\n        At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor\n        (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different\n        regimens with at least one protease inhibitor).\n\n        Alcohol or illicit drug use that may interfere with the patient's compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002200", 
            "org_study_id": "238M", 
            "secondary_id": "CNAA3008"
        }, 
        "intervention": {
            "intervention_name": "Abacavir sulfate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Reverse Transcriptase Inhibitors", 
                "Abacavir"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Administration, Oral", 
            "CD4 Lymphocyte Count", 
            "RNA, Viral", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Research Triangle Park", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "277093398"
                }, 
                "name": "Glaxo Wellcome Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A 1592U89 Open-Label Protocol for Adult Patients With HIV-1 Infection.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002200"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1998"
    }, 
    "geocoordinates": {
        "Glaxo Wellcome Inc": "35.902 -78.867"
    }
}